Storm at the Time of Corona: A Glimpse at the Current Understanding and Therapeutic Opportunities of the SARS-CoV-2 Cytokine Storm

Author(s): Monireh Torabi-Rahvar, Nima Rezaei*

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 13 , 2021

Become EABM
Become Reviewer
Call for Editor


Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may lead to severe disease in some cases, leading to acute respiratory distress syndrome, multi-organ failure, and death. This severe phenotype seems to be associated with a cytokine storm and immune dysregulation. Increased pro-inflammatory cytokines and CD14+CD16+ inflammatory monocytes, lymphopenia, and decreased levels of regulatory T cells are some of the immunological features that are seen in patients with SARS-CoV-2. As the outcome of SARS-CoV-2 is influenced by both viral virulence and dysregulated inflammatory response, a combination therapy approach using antiviral drugs plus anti-inflammatory treatments, such as corticosteroids, monoclonal antibodies against the IL-6 and IL-1β pathways, and JAK inhibitors are under clinical trials.

Keywords: Severe acute respiratory syndrome coronavirus 2, cytokine storm, proinflammatory cytokines, monoclonal antibodies, inflammatory, IL-1β.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 19 May, 2021
Page: [1549 - 1552]
Pages: 4
DOI: 10.2174/1381612826666201125102649
Price: $65

Article Metrics

PDF: 151